Is SGMT diluting shareholders?

Read three numbers together: shares outstanding over time (30.7M as of 2024-11-08), warrants that can convert into new shares, and how much cash runway remains (~63.12236582694414 months). A company short on cash with live registrations is structurally likely to issue shares.

Where do these numbers come from?

SEC EDGAR only: the XBRL company-facts API for shares, warrants and cash, and filing metadata for registrations and pricings. Every figure shows its source form, and nothing here is estimated by us beyond the arithmetic stated next to it.

Why might a warrant tranche be missing from the table?

The tranche table is built from the dimensions the company tagged in its own 10-Q or 10-K XBRL. A tranche the filer chose not to dimension does not appear, and its absence proves nothing: the exhibits remain the ground truth. Everything shown carries the filing it came from.

Dilution profile // every instrument, one screen, from SEC filings

Sagimet Biosciences Inc. (SGMT)

CIK 1400118 · all EDGAR filings →

Overall dilution risk

HIGHworst of 3 computed signals (offering ability)

= the worst band among the computed sub-ratings, no hidden weighting

not every sub-rating was computable; treat as a floor

Offering ability

HIGHS-3 on file 2024-08-15

= is there a registration (S-1/S-3 family) on file without a later withdrawal

no structured fee data on the live registrations, so this is a yes/no, not a size

Overhead supply

NOT COMPUTEDno warrant count tagged in XBRL

= warrant shares outstanding divided by current shares outstanding

absence of a tag is not proof of absence of warrants

Historical dilution

MEDIUM+44% O/S in 3y

= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative

Cash need

LOW~63.1 months of runway

= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

Latest: 30.7M shares as of Nov 8, 2024 (10-Q).

Cash runway

Self-funding

generates cash

Full breakdown: cash runway tool · source filing →

Warrants

Tranche	Warrants	Exercise price	Term	Notes
Series Common Stock Warrants	1,000	$69.94	—	—

Tranches exactly as the company dimensioned them in its 10-Q filed Aug 11, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

Balance-sheet fair value of warrants: $4,000 as of Dec 31, 2022.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 11, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding	30.7M	Nov 8, 2024
+ Series Common Stock Warrants (if exercised)	1,000	Jun 30, 2026
Fully diluted estimate	30.7M	+0.0% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

S-3Aug 15, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

S-1Jan 23, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 2 executed · 0 registered.

EXECUTEDApr 28, 2026Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →

EXECUTEDAug 14, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →

EFFECTIVEAug 26, 2024SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDAug 15, 2024S-3 registration — capacity to sell shares, not a sale yetS-3 →

EXECUTEDJan 29, 2024Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4 →

EFFECTIVEJan 25, 2024SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDJan 24, 2024S-1/A registration — capacity to sell shares, not a sale yetS-1/A →

REGISTEREDJan 23, 2024S-1 registration — capacity to sell shares, not a sale yetS-1 →

EXECUTEDJul 17, 2023Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4 →

REGISTEREDJul 13, 2023S-1MEF registration — capacity to sell shares, not a sale yetS-1MEF →

EFFECTIVEJul 13, 2023SEC declared a registration effective — selling can beginEFFECT →

REGISTEREDJul 10, 2023S-1/A registration — capacity to sell shares, not a sale yetS-1/A →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full SGMT workspace